Idera Pharmaceuticals (NASDAQ: IDRA) is one of 198 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Idera Pharmaceuticals to similar companies based on the strength of its risk, profitability, institutional ownership, valuation, analyst recommendations, earnings and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Idera Pharmaceuticals and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Idera Pharmaceuticals 0 0 5 0 3.00
Idera Pharmaceuticals Competitors 478 2262 6182 119 2.66

Idera Pharmaceuticals currently has a consensus target price of $5.75, suggesting a potential upside of 163.76%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.46%. Given Idera Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Idera Pharmaceuticals is more favorable than its rivals.

Earnings and Valuation

This table compares Idera Pharmaceuticals and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Idera Pharmaceuticals $16.17 million -$42.73 million -6.61
Idera Pharmaceuticals Competitors $207.79 million -$2.30 million 0.43

Idera Pharmaceuticals’ rivals have higher revenue and earnings than Idera Pharmaceuticals. Idera Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Idera Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Idera Pharmaceuticals -300.63% -61.09% -55.14%
Idera Pharmaceuticals Competitors -3,554.56% -117.73% -43.15%

Risk & Volatility

Idera Pharmaceuticals has a beta of 2.23, meaning that its stock price is 123% more volatile than the S&P 500. Comparatively, Idera Pharmaceuticals’ rivals have a beta of 1.63, meaning that their average stock price is 63% more volatile than the S&P 500.

Institutional and Insider Ownership

30.9% of Idera Pharmaceuticals shares are held by institutional investors. Comparatively, 48.7% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 30.3% of Idera Pharmaceuticals shares are held by company insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Idera Pharmaceuticals beats its rivals on 7 of the 12 factors compared.

About Idera Pharmaceuticals

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company’s drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.

Receive News & Ratings for Idera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.